SecurityFNBG / FNB Bancorp (302515101)
CEOMCGRAW THOMAS C
IndustryState Commercial Banks
Institutional Owners50
Institutional Shares1,834,245 - 24.52%
Common Shares Outstanding7,480,538 shares (as of 2018-03-31)
Institutional Value$ 98,003,000 USD
Related FBIP / FNB Bancorp, Inc.

Institutional Stock Ownership and Shareholders

FNB Bancorp (NASDAQ:FNBG) has 50 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,834,245 shares. Largest shareholders include Brown Trout Management, LLC, Vanguard Group Inc, BlackRock Inc., Mount Yale Investment Advisors, Llc, Banc Funds Co Llc, State Street Corp, Renaissance Technologies LLC, Northern Trust Corp, Dimensional Fund Advisors Lp, and Css Llc/il.
FNB Bancorp (NASDAQ:FNBG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-07 13F-HR SG Americas Securities, LLC 2,812 0 -100.00 103 0 -100.00
2018-08-14 13F-HR UBS Group AG 175 664 279.43 6 24 300.00
2018-08-13 13F-HR CAPSTONE INVESTMENT ADVISORS, LLC 7,220 265
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 505 885 75.25 19 33 73.68
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 0 455 0 17
2018-05-11 13F-HR Delpha Capital Management, Llc 16 0 -100.00 1 0 -100.00
2018-08-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 13,027 11,614 -10.85 479 426 -11.06
2018-08-14 13F-HR DEUTSCHE BANK AG\ 31,267 30,362 -2.89 1,149 1,112 -3.22
2018-08-10 13F-HR Brown Trout Management, LLC 479,080 543,115 13.37 17,625 19,916 13.00
2018-08-02 13F-HR D.A. DAVIDSON & CO. 7,342 269
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 466 466 0.00 17 17 0.00
2018-07-27 13F-HR PIEDMONT INVESTMENT ADVISORS LLC 90 3
2018-08-14 13F-HR ROYAL BANK OF CANADA 220 0 -100.00 8 0 -100.00
2018-08-14 13F-HR JP Morgan Chase & Co 1,085 1,286 18.53 40 48 20.00
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 365 163 -55.34 13,428 5,977 -55.49
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 39,432 45,754 16.03 1,451 1,678 15.64
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 21,912 21,912 0.00 806 803 -0.37
2018-08-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 13,000 13,000 0.00 478 477 -0.21
2018-07-24 13F-HR MEEDER ASSET MANAGEMENT INC 1,066 676 -36.59 39 24,789 63,461.54
2018-08-13 13F-HR BANC FUNDS CO LLC 172,641 94,823 -45.08 6,351 3,477 -45.25
2018-08-22 13F-HR Mount Yale Investment Advisors, Llc 126,295 4,631
2018-08-03 13F-HR WEDBUSH SECURITIES INC 6,608 6,608 0.00 243 242 -0.41
2018-08-14 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 8,350 7,889 -5.52 307 289 -5.86
2018-08-14 13F-HR BARCLAYS PLC 1,134 391 -65.52 42 15 -64.29
2018-08-14 13F-HR STATE STREET CORP 80,623 85,176 5.65 2,965 3,124 5.36
2018-08-10 13F-HR CITIGROUP INC 1,115 771 -30.85 41 28 -31.71
2018-07-24 13F-HR RAMSEY QUANTITATIVE SYSTEMS 619 1,007 62.68 23 37 60.87
2018-08-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 12,477 22,146 77.49 459 812 76.91
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 5,079 4,972 -2.11 187 182 -2.67
2018-08-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 5,700 5,700 0.00 210 209 -0.48
2018-08-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 32 32 0.00 1 1 0.00
2018-08-09 13F-HR BlackRock Inc. 228,108 246,499 8.06 8,393 9,040 7.71
2018-08-06 13F-HR STRS OHIO 500 500 0.00 18 18 0.00
2018-08-14 13F-HR MORGAN STANLEY 11,790 12,299 4.32 434 451 3.92
2018-05-11 13F-HR CITIGROUP INC 787 1,115 41.68 29 41 41.38
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 20,605 19,505 -5.34 758 715 -5.67
2018-08-06 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 50,404 4,992 -90.10 1,854 183 -90.13
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 37 0 1
2018-09-18 13F-HR/A NORTHERN TRUST CORP 50,688 48,963 -3.40 1,865 1,795 -3.75
2018-08-13 13F-HR Renaissance Technologies LLC 56,800 2,090
2018-07-30 13F-HR Parallel Advisors, LLC 18 18 0.00 1 0 -100.00
2018-08-14 13F-HR Walleye Trading LLC 10,850 0 -100.00 399 0 -100.00
2018-08-14 13F-HR VANGUARD GROUP INC 273,301 277,268 1.45 10,054 10,167 1.12
2018-08-14 13F-HR STIFEL FINANCIAL CORP 9,943 9,441 -5.05 365 346 -5.21
2018-08-14 13F-HR DLD Asset Management, LP 10,000 10,000 0.00 368 367 -0.27
2018-08-14 13F-HR CSS LLC/IL 35,169 1,290
2018-08-14 13F-HR TEACHERS ADVISORS INC 9,206 9,206 0.00 339 338 -0.29
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 16,843 19,781 17.44 619 725 17.12
2018-08-14 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 13,105 10,755 -17.93 482 394 -18.26
2018-08-13 13F-HR Round Hill Asset Management 8,920 8,920 0.00 328 327 -0.30
2018-08-10 13F-HR Legal & General Group Plc 1,021 780 -23.60 38 29 -23.68
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 9,358 5,417 -42.11 344 199 -42.15
2018-08-08 13F-HR AMERICAN INTERNATIONAL GROUP INC 3,447 3,358 -2.58 127 123 -3.15
2018-08-08 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 8,700 8,700 0.00 321 320 -0.31
2018-08-13 13F-HR Ativo Capital Management LLC 19,000 0 -100.00 699 0 -100.00
2018-07-27 13F-HR FIRST QUADRANT L P/CA 3,908 3,908 0.00 144 143 -0.69

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Stocks To Watch: Tariffs Don't Take Holidays

2018-06-30 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a shortened week due to the Independence Day holiday -- a "trading week interruptus," with July 4 landing on Wednesday. (254-5)

CUSIP: 302515101